Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 246 participants.
Also called NCT06946095
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 246 participants
- Sponsor
- Registry
-
NCT06946095
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT06946095. Randomized; no masking; primary purpose treatment. Start 2025-05-20 (anticipated); primary completion 2027-10-31 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Xinyue Capsule in the Treatment of Heart Failure With Preserved Ejection Fraction
- Condition
- Heart Failure
- Intervention (Drug)
- Chinese patent medicine
- Lead sponsor
- Beijing Anzhen Hospital
Record details
- Record id
cardio:ct-nct06946095- Content hash
fa73bbe66c753baf4a53f0107bb96aa99e7306d6954f3af7344c0779d66891a2